$NRXP Cashflow Statement | Understand Stock

$NRXP

$2.69 +$0.14 (5.49%) Close

$NRXP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
Depreciation and amortization expense
Amortization of operating right of use assets
Stock-based compensation
Provision (recovery) for expected credit losses
Common Stock issued in exchange for services
Change in fair value of warrant liabilities
Change in fair value of earnout cash liability
Change in fair value of convertible promissory note
Non-cash interest expense
Non-cash consulting expense
Change in fair value of convertible promissory notes
Loss on convertible note conversions
Gain on exercise of warrant liabilities
Loss on issuance of registered direct Common Stock
Loss on debt settlement
Loss on equity method investments
Expense for debt issuance costs due to fair value election on Anson Notes
Warrant issuance costs related to Alvogen termination
Convertible note default penalty
Non-cash settlement expense

Changes in operating assets and liabilities:
Prepaid expense and other assets
Account receivable
Accounts payable
Operating lease liabilities
Accrued expense and other liabilities
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Business acquisition, net of cash acquired
Cash used in investments
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of convertible note
Repayment of insurance note
Expense for debt issuance costs due to fair value election on Anson Notes
Proceeds from issuance of insurance loan
Proceeds from Anson convertible note, net
Proceeds from stock option exercise
Repayment of note payable
Repayment of insurance loan
Proceeds from liability classified warrants
Proceeds from issuance of Series A preferred stock and warrants issued in private placement, net of issuance costs
Repayment of notes payable assumed in Merger
Repayment of notes payable - related party
ATM offering, net of offering costs
Proceeds from issuance of Common Stock and warrants, net of issuance costs
Consideration Warrants
Warrants Other Than Consideration Warrants
Total proceeds from issuance of Common Stock and warrants, net of issuance costs
Proceeds from issuance of Common Stock and warrants issued in private placement, net of issuance costs
Proceeds from issuance of common stock and exercise of stock options, net of transaction costs
Net cash provided by financing activities

Net increase in cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Reclassification of settlement liability upon issuance of warrant
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosure of cash flow information:
Cash paid for interest
Issuance of common stock as principal and interest repayment for convertible notes
Issuance of common stock warrants as offering costs
Extinguishment of Paycheck Protection Program Loan
Cash paid for taxes

Non-cash investing and financing activities:
Issuance of Common Stock as principal and interest repayment for convertible notes
Issuance of Common Stock warrants as offering costs
Recognition of assets acquired as part of business combination (non-cash)
Recognition of liabilities assumed as part of business combination (non-cash)
Right-of-use assets obtained in exchange for operating lease liability
Stock issued due to VWAP adjustments
Warrants issued due to VWAP adjustments
Amortization of deferred offering costs to additional paid-in capital
Conversion of Series A preferred stock into Common Stock

Comments